MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

Grifols SA

Отворен

СекторФинансови

8.472 0.57

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.42

Максимум

8.564

Ключови измерители

By Trading Economics

Приходи

17M

69M

Продажби

183M

2B

P/E

Средно за сектора

36.313

20.525

EPS

0.101

Марж на печалбата

3.491

Служители

23,833

EBITDA

57M

482M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+65.92% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.6B

5.2B

Предишно отваряне

7.9

Предишно затваряне

8.472

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Grifols SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2025 г., 17:19 ч. UTC

Придобивния, сливания и поглъщания

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2.04.2025 г., 13:02 ч. UTC

Придобивния, сливания и поглъщания

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2.04.2025 г., 10:13 ч. UTC

Придобивния, сливания и поглъщания

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8.07.2024 г., 10:40 ч. UTC

Придобивния, сливания и поглъщания

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8.07.2024 г., 09:13 ч. UTC

Придобивния, сливания и поглъщания

Grifols Faces Delisting Bid From Founding Family and Brookfield

15.04.2025 г., 09:55 ч. UTC

Пазарно говорене

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Grifols SA Прогноза

Ценова цел

By TipRanks

65.92% нагоре

12-месечна прогноза

Среден 14.02 EUR  65.92%

Висок 19.05 EUR

Нисък 11 EUR

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Grifols SA през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

2

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

8.006 / 8.544Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.